Business
NetraMark Signs Contract With Global Biopharmaceutical Company to Analyze Phase 2 Depression Trial Data
Agreement further extends NetraMark’s portfolio of AI-driven projects in depression and ce...
About this update from Netramark Holdings Inc
[{"type":"text","content":"NetraMark Signs Contract With Global Biopharmaceutical Company to Analyze Phase 2 Depression Trial Data\nAgreement further extends NetraMark’s portfolio of AI-driven projects in depression and central nervous system (CNS) disorders TORONTO, March 11, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0),  a company developing advanced artificial intelligence solutions for clinical trial optimization and precision medicine for the pharmaceutical industry, today announced that it signed a new contract with a leading global biopharmaceutical company developing innovative treatments for psychiatric and neurological disorders. The agreement will allow NetraMark to analyze data from this client’s Phase 2 clinical trial for depression. This collaboration supports NetraAI’s continued use in the pharmaceutical industry as an AI driven approach to understanding patient heterogeneity, dosing decisions, and supporting study success rates. “We believe this engagement reflects the demand from pharmaceutical companies to better understand the patient heterogeneity in clinical trials,” said George Achilleos, Chief Executive Officer of NetraMark. “By analyzing this Phase 2 dataset, we aim to identify the patient subpopulations most likely to benefit from treatment and provide insights that may inform our sponsor’s future study design with greater precision and confidence.” Under the agreement, NetraMark will deploy its proprietary AI methodology to perform analyses on multi-dimensional clinical data to uncover potential patient phenotypes, evaluate treatment-related response patterns, and generate hypothesis-driven insights. This engagement further extends NetraMark’s growing portfolio of AI-driven projects in depression and CNS disorders as the Company continues to demonstrate its capacity to deliver actionable precision-trial insights that support drug development success for its clients. NetraMark’s NetraAI platform leverages a dynamical systems framework which seeks to overcome the limitations of traditional machine learning, allowing it to work effectively with complex, small clinical datasets. The system is capable of stratifying high-effect-size patient subpopulations ...